Pure Global AI
NCT06375031Not yet recruiting

Comparison of HR011408 and NovoRapid® in Subjects With Diabetics

Comparing Pharmacokinetics and Pharmacodynamics Between HR011408 and NovoRapid® in Subjects With Diabetics- A Randomized, Double-Blind, Three-cycle Crossover Phase I Clinical Trial
Jiangsu HengRui Medicine Co., Ltd.Phase 1ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes
Drug/Device/Intervention
HR011408 injection; HR011408 injection Placebo
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Jiangsu HengRui Medicine Co., Ltd.
Location
Hefei, China
Timeline & enrollment
Phase
Phase 1
Start date
Apr 01, 2024
End date
Jul 15, 2024
Enrollment
30 participants
Primary outcome

Area under the serum concentration-time curve of insulin aspart

Summary

The objective of the study is to compare the pharmacokinetics and pharmacodynamics between
 HR011408 and NovoRapid® in Subjects with Diabetics.

ICD-10 classifications
Diabetes mellitusUnspecified diabetes mellitusOther specified diabetes mellitusUnspecified diabetes mellitus without complicationsOther specified diabetes mellitus without complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06375031
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06375031 through Pure Global AI's free database. This Phase 1 trial is sponsored by Jiangsu HengRui Medicine Co., Ltd. and is currently Not yet recruiting. The study focuses on Diabetes. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.